Proposed Ohio Legislation Could Change How Marijuana Impairment Is Evaluated in OVI Cases

As Ohio continues to refine its approach to marijuana regulation, lawmakers are now turning their attention to how cannabis use is evaluated in impaired driving cases. In early 2026, proposed legislation signals a significant shift away from outdated testing methods and toward a more scientifically grounded standard focused on actual impairment.

What is Senate Bill 55?

At the center of this effort is Senate Bill 55 (SB 55), which has already passed the Ohio Senate and is currently under consideration in the House of Representatives. The bill builds on broader cannabis reforms implemented under Senate Bill 56 (SB 56), which took effect on March 20, 2026, and introduced stricter rules for adult-use cannabis, including changes to hemp classification and transportation regulations.

Key Change: Eliminating Metabolite Testing

One of the most notable changes proposed in SB 55 is the elimination of marijuana metabolite testing as a basis for automatic OVI (Operating a Vehicle Impaired) convictions. Under current law, drivers can be convicted based solely on the presence of inactive marijuana metabolites—compounds that can remain in the body for weeks after use and do not indicate impairment. Critics have long argued that this standard risks penalizing individuals who are not actually impaired at the time of driving.

What Would Replace It?

In place of this system, SB 55 proposes a more nuanced, inference-based approach. The bill would raise the legal threshold for active Delta-9 THC in whole blood from 2 nanograms per milliliter to 5 nanograms per milliliter. Rather than triggering an automatic conviction, THC levels within a specified range—such as 2 to 5 ng/mL in blood or 25 ng/mL in urine—would allow courts to infer impairment. However, drivers would retain the ability to present evidence to challenge that inference, introducing greater flexibility and fairness into the process.

Where Things Stand Now and What’s Ahead

Despite these proposed reforms, the current legal framework remains in effect as of late March 2026. Because SB 55 has not yet been approved by the Ohio House or signed by the governor, Ohio continues to enforce its stricter standards, including the use of metabolite-based per se limits in OVI cases.

If enacted, SB 55 would represent a meaningful evolution in Ohio law—aligning enforcement more closely with actual impairment and reducing the likelihood of convictions based on residual, non-impairing substances. Until then, however, drivers remain subject to the existing rules, underscoring the importance of understanding how current laws are applied.

We are continuing to monitor this legislation as it moves through the Ohio House. If you have any questions about how these developments may impact you, please reach out to David Gast at dmgast@strausstroy.com or 513.629.9485.